Nabriva Therapeutics (NBRV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 21,000 ordinary shares of Nabriva Therapeutics as an inducement to one newly-hired employee. The award was made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The stock options were granted effective February 28, 2020 with an exercise price of $1.35 per share, which is equal to the closing price of Nabriva Therapeutics’s ordinary shares on the date of grant.
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Open Forum Infectious Diseases, an official journal of the Infectious Diseases Society of America (IDSA), has published results from a post-hoc analysis of clinical data from patients who initiated treatment in the hospital from the pivotal Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 clinical trials. The analyses indicate that lefamulin results in a rapid and similar time to clinical response, a proxy for hospital “discharge readiness,” compared to moxifloxacin.
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the BofA Securities 2020 Virtual Health Care Conference on Wednesday, May 13, at 11:00a.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA™ (lefamulin), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results after the close of the U.S. financial markets on Monday, May 11, 2020. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com.
NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Nabriva Therapeutics Plc (NASDAQ:NBRV) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at ...
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 4, at 1:00p.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA™ (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
Amicus (FOLD) posts a wider-than-expected loss, while sales beat estimates in the fourth quarter of 2019.
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…
-Cash runway extended into the fourth quarter of 2020 through judicious resource management- -XENLETA managed care coverage and patient reimbursement continues to.
Upgrades * Morgan Stanley changed the rating for Westinghouse Air Brake Technologies Corp (NYSE: WAB) from Equal-Weight to Overweight. For the fourth quarter, Westinghouse Air Brake had an EPS of $1.04, compared to year-ago quarter EPS of $0.97. The stock has a 52-week-high of $81.75 and a 52-week-low of $47.57. Westinghouse Air Brake's stock last closed at $48.19 per share. * Oppenheimer changed the rating for Walmart Inc (NYSE: WMT) from Perform to Outperform. For the fourth quarter, Walmart had an EPS of $1.43, compared to year-ago quarter EPS of $1.41. The stock has a 52-week-high of $125.38 and a 52-week-low of $96.53. Walmart's stock last closed at $106.75 per share. * Baird upgraded the stock for Heartland Express Inc (NASDAQ: HTLD) from Neutral to Outperform. In the fourth quarter, Heartland Express showed an EPS of $0.16, compared to $0.27 from the year-ago quarter. The stock has a 52-week-high of $22.71 and a 52-week-low of $15.65. Heartland Express's stock last closed at $15.78 per share. * For MetLife Inc (NYSE: MET), Citigroup upgraded the stock from Sell to Neutral. MetLife earned $1.98 in the fourth quarter, compared to $1.35 in the year-ago quarter. The stock has a 52-week-high of $53.28 and a 52-week-low of $26.00. MetLife's stock last closed at $26.84 per share. * Morgan Stanley changed the rating for Oshkosh Corp (NYSE: OSK) from Equal-Weight to Overweight. For the first quarter, Oshkosh had an EPS of $1.10, compared to year-ago quarter EPS of $1.61. The stock has a 52-week-high of $95.62 and a 52-week-low of $53.26. Oshkosh's stock last closed at $53.80 per share. * DA Davidson upgraded the stock for AppFolio Inc (NASDAQ: APPF) from Underperform to Neutral. For the fourth quarter, AppFolio had an EPS of $0.12, compared to year-ago quarter EPS of $0.07. The stock has a 52-week-high of $148.07 and a 52-week-low of $73.20. AppFolio's stock last closed at $84.99 per share. Downgrades * For Nabriva Therapeutics PLC (NASDAQ: NBRV), Morgan Stanley downgraded the stock from Overweight to Equal-Weight. For the fourth quarter, Nabriva Therapeutics had an EPS of ($0.29), compared to year-ago quarter EPS of ($0.46). The stock has a 52-week-high of $3.27 and a 52-week-low of $0.50. Nabriva Therapeutics's stock last closed at $0.63 per share. * For Fortinet Inc (NASDAQ: FTNT), DA Davidson downgraded the stock from Buy to Neutral. In the fourth quarter, Fortinet showed an EPS of $0.76, compared to $0.59 from the year-ago quarter. The stock has a 52-week-high of $121.82 and a 52-week-low of $68.87. Fortinet's stock last closed at $75.70 per share. * For Imax Corp (NYSE: IMAX), Benchmark downgraded the stock from Buy to Hold. In the fourth quarter, Imax showed an EPS of $0.35, compared to $0.26 from the year-ago quarter. The stock has a 52-week-high of $25.75 and a 52-week-low of $8.91. Imax's stock last closed at $9.14 per share. * Benchmark downgraded the stock for Internap Corp (NASDAQ: INAP) from Buy to Hold. For the third quarter, Internap had an EPS of ($0.85), compared to year-ago quarter EPS of ($0.56). The stock has a 52-week-high of $5.67 and a 52-week-low of $0.08. Internap's stock last closed at $0.14 per share. * DA Davidson changed the rating for Tufin Software Technologies Ltd (NYSE: TUFN) from Buy to Neutral. Tufin Software earned ($0.07) in the fourth quarter, compared to $0.13 in the year-ago quarter. The stock has a 52-week-high of $31.04 and a 52-week-low of $6.08. Tufin Software's stock last closed at $7.50 per share. * Raymond James downgraded the stock for Brigham Minerals Inc (NYSE: MNRL) from Strong Buy to Outperform. Brigham Minerals earned $0.36 in the fourth quarter. The stock has a 52-week-high of $23.29 and a 52-week-low of $8.32. Brigham Minerals's stock last closed at $8.77 per share. * Raymond James downgraded the stock for Parsley Energy Inc (NYSE: PE) from Strong Buy to Outperform. For the fourth quarter, Parsley Energy had an EPS of $0.28, compared to year-ago quarter EPS of $0.30. The stock has a 52-week-high of $22.11 and a 52-week-low of $4.77. Parsley Energy's stock last closed at $5.31 per share. * For Pioneer Natural Resources Co (NYSE: PXD), Raymond James downgraded the stock from Strong Buy to Outperform. In the fourth quarter, Pioneer Natural Resources showed an EPS of $2.36, compared to $1.18 from the year-ago quarter. The stock has a 52-week-high of $178.22 and a 52-week-low of $57.24. Pioneer Natural Resources's stock last closed at $59.70 per share. * Raymond James downgraded the stock for Viper Energy Partners LP (NASDAQ: VNOM) from Strong Buy to Outperform. In the fourth quarter, Viper Energy Partners showed an EPS of $0.03, compared to $0.10 from the year-ago quarter. The stock has a 52-week-high of $34.93 and a 52-week-low of $7.00. Viper Energy Partners's stock last closed at $8.25 per share. * Raymond James downgraded the stock for YPF SA (NYSE: YPF) from Strong Buy to Outperform. In the third quarter, YPF earned ($0.04). The stock has a 52-week-high of $18.73 and a 52-week-low of $3.30. YPF's stock last closed at $3.86 per share. * Raymond James downgraded the stock for Apache Corp (NYSE: APA) from Outperform to Market Perform. Apache earned $0.08 in the fourth quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $38.12 and a 52-week-low of $5.45. Apache's stock last closed at $5.45 per share. * Raymond James changed the rating for California Resources Corp (NYSE: CRC) from Outperform to Market Perform. California Resources earned $0.73 in the fourth quarter, compared to $0.53 in the year-ago quarter. The stock has a 52-week-high of $30.18 and a 52-week-low of $2.50. California Resources's stock last closed at $3.16 per share. * Raymond James downgraded the stock for Kosmos Energy Ltd (NYSE: KOS) from Outperform to Market Perform. Kosmos Energy earned ($0.09) in the fourth quarter, compared to ($0.09) in the year-ago quarter. The stock has a 52-week-high of $7.55 and a 52-week-low of $0.66. Kosmos Energy's stock last closed at $0.67 per share. * For TRI Pointe Group Inc (NYSE: TPH), B. Riley FBR downgraded the stock from Buy to Neutral. TRI Pointe Group earned $0.85 in the fourth quarter, compared to $0.79 in the year-ago quarter. The stock has a 52-week-high of $18.63 and a 52-week-low of $8.85. TRI Pointe Group's stock last closed at $8.99 per share. * Raymond James changed the rating for Matador Resources Co (NYSE: MTDR) from Outperform to Market Perform. Matador Resources earned $0.39 in the fourth quarter, compared to $0.37 in the year-ago quarter. The stock has a 52-week-high of $22.25 and a 52-week-low of $1.59. Matador Resources's stock last closed at $1.74 per share. * B. Riley FBR changed the rating for Tecnoglass Inc (NASDAQ: TGLS) from Buy to Neutral. Tecnoglass earned $0.16 in the fourth quarter, compared to $0.27 in the year-ago quarter. The stock has a 52-week-high of $8.93 and a 52-week-low of $2.80. Tecnoglass's stock last closed at $2.89 per share. * B. Riley FBR downgraded the stock for RCM Technologies Inc (NASDAQ: RCMT) from Buy to Neutral. RCM Technologies earned $0.08 in the fourth quarter, compared to $0.05 in the year-ago quarter. The stock has a 52-week-high of $4.20 and a 52-week-low of $1.29. RCM Technologies's stock last closed at $1.39 per share. * B. Riley FBR changed the rating for ProPetro Holding Corp (NYSE: PUMP) from Buy to Neutral. In the third quarter, ProPetro Holding showed an EPS of $0.33, compared to $0.53 from the year-ago quarter. The stock has a 52-week-high of $25.38 and a 52-week-low of $1.44. ProPetro Holding's stock last closed at $2.53 per share. * B. Riley FBR downgraded the stock for PGT Innovations Inc (NYSE: PGTI) from Buy to Neutral. For the fourth quarter, PGT Innovations had an EPS of $0.10, compared to year-ago quarter EPS of $0.21. The stock has a 52-week-high of $18.48 and a 52-week-low of $8.48. PGT Innovations's stock last closed at $8.54 per share. * B. Riley FBR changed the rating for Legacy Housing Corp (NASDAQ: LEGH) from Buy to Neutral. In the third quarter, Legacy Housing showed an EPS of $0.25, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $17.50 and a 52-week-low of $8.93. Legacy Housing's stock last closed at $10.55 per share. Initiations * With a rating of Sector Perform, RBC Capital initiated coverage on J2 Global Inc (NASDAQ: JCOM). The price target is set at $83.00 for J2 Global. For the fourth quarter, J2 Global had an EPS of $2.38, compared to year-ago quarter EPS of $2.11. The stock has a 52-week-high of $104.57 and a 52-week-low of $68.67. J2 Global's stock last closed at $68.82 per share.See more from Benzinga * 15 Consumer Cyclical Stocks Moving In Tuesday's Pre-Market Session * 18 Healthcare Stocks Moving In Tuesday's Pre-Market Session * 9 Consumer Defensive Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
-Prioritizing community opportunity for oral XENLETA given broad reimbursement coverage- -Reducing balance sheet risk through early paydown of a substantial portion of Hercules.
Nabriva (NBRV) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite inv…
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary decision to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for XENLETA™ (lefamulin) 150 mg injection. Having a unique J-code for XENLETA will help facilitate more efficient billing for hospitals and will assist in the tracking of XENLETA in claims data. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, at 11:20a.m. ET. Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA™ (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
Nabriva Therapeutics (NBRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 161,000 ordinary shares of Nabriva Therapeutics as inducements to 5 newly-hired employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation. The stock options were granted effective January 31, 2020 with an exercise price of $1.35 per share, which is equal to the closing price of Nabriva Therapeutics’ ordinary shares on the date of grant.
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced the publication of a study entitled, A Multicenter Evaluation of the U.S. Prevalence and Regional Variation in Macrolide Resistant S. pneumoniae from Blood or Respiratory Cultures among Adult Patients (Abstract #5523), online in the proceedings of 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID). This study assessed 3,510 patients with a positive S. pneumoniae blood or respiratory culture in the ambulatory and inpatient setting at 329 hospitals across nine U.S. Census geographic regions over 12 months ending 3Q2019 to determine the prevalence and rates of macrolide resistance in S. pneumoniae.
Nabriva Therapeutics plc (NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its fourth quarter and full year 2019 financial results after the close of the U.S. financial markets on Thursday, March 12, 2020. Nabriva’s management will host a conference call at 4:30 p.m. ET to discuss the financial results and recent corporate highlights. A live webcast of the conference call can be accessed through the “Investors” tab on the Nabriva Therapeutics website at www.nabriva.com.
As of late, it has definitely been a great time to be an investor in Nabriva Therapeutics.